Yahoo · Oct 8, 2026
European Equities Traded in US as ADRs Fall in Thursday Trading
European equities traded in the US as American depositary receipts fell late Thursday morning with t
CL
NASDAQ · CLLS
Cellectis S.A.
Healthcare · Biotechnology
$1.08
Down-$0.09 (-7.69%)
Updated Nov 1, 2026, 5:57 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 523.7M
- P/E ratio
- -8.66
- Dividend yield
- 0.00%
- 52-week range
- $0.88 – $4.55
- Volume
- 12.27K
- Avg. volume
- 146.61K
Price performance · CLLS
CLLS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CLLS closed at $1.08 after 20 trading sessions, down 23.40% for the selected period.
- Last close
- $1.08
- Period change
- -23.40%
- Period low
- $0.93
- Period high
- $1.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.15 | $1.15 | $1.07 | $1.08 | 12.27K |
| Oct 29, 2026 | $1.22 | $1.23 | $1.15 | $1.17 | 26.66K |
| Oct 28, 2026 | $1.10 | $1.28 | $1.0825 | $1.26 | 256.57K |
| Oct 27, 2026 | $0.9632 | $1.05 | $0.9632 | $1.05 | 78.3K |
| Oct 26, 2026 | $0.98 | $1.01 | $0.9309 | $0.9665 | 45.34K |
| Oct 23, 2026 | $1.00 | $1.0175 | $0.959 | $0.98 | 13.63K |
| Oct 22, 2026 | $0.97 | $1.0099 | $0.9177 | $0.975 | 129.35K |
| Oct 21, 2026 | $1.07 | $1.08 | $0.9106 | $0.9685 | 282.1K |
| Oct 20, 2026 | $0.94 | $1.03 | $0.93 | $0.99 | 281.75K |
| Oct 19, 2026 | $1.04 | $1.04 | $0.8808 | $0.9255 | 224.84K |
| Oct 16, 2026 | $1.12 | $1.12 | $1.03 | $1.04 | 81.37K |
| Oct 15, 2026 | $1.14 | $1.14 | $1.09 | $1.105 | 101.43K |
| Oct 14, 2026 | $1.12 | $1.1499 | $1.10 | $1.12 | 99.08K |
| Oct 13, 2026 | $1.175 | $1.175 | $1.09 | $1.10 | 54.42K |
| Oct 12, 2026 | $1.25 | $1.28 | $1.14 | $1.18 | 122.57K |
| Oct 9, 2026 | $1.27 | $1.29 | $1.25 | $1.26 | 75.76K |
| Oct 8, 2026 | $1.28 | $1.3061 | $1.2205 | $1.25 | 106.83K |
| Oct 7, 2026 | $1.35 | $1.40 | $1.33 | $1.34 | 62.46K |
| Oct 6, 2026 | $1.42 | $1.44 | $1.37 | $1.40 | 75.79K |
| Oct 5, 2026 | $1.43 | $1.4369 | $1.38 | $1.41 | 37.27K |
Latest CLLS news
The latest Smart Investors Daily articles mentioning CLLS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CLLS research
Overview
Company profile and research snapshot.
Company profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | ODDO BHF | Buy | — |
| Sep 14, 2026 | JEFFERIES | Buy | — |
| Aug 12, 2026 | CITIZENS | Outperform | — |
| Jul 8, 2026 | ODDO BHF | Buy | — |
| Jul 7, 2026 | ODDO BHF | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 7, 2026
European Equities Traded in US as ADRs Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell late Wednesday morning with
Yahoo · Feb 26, 2026
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
European equities traded in the US as American depositary receipts were sharply lower late Thursday
Yahoo · Feb 17, 2026
European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were marginally lower late Tuesda
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
